Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity - PubMed
- ️Thu Jan 01 2004
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
Ursula J Buchholz et al. Proc Natl Acad Sci U S A. 2004.
Abstract
We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.
Figures
![Fig. 1.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8cf/470755/9a7ea5a5767f/zpq0260452540001.gif)
Maps of the genomes of BHPIV3 vectors expressing the SARS-CoV S, M, E, and N ORFs or a heterologous control sequence equivalent in length to the S ORF. The BPIV3 backbone genes are shown as open rectangles, the HPIV3 surface protein genes are checked rectangles, and the SARS-CoV ORFs and control sequence are shaded rectangles. PIV3 gene-start and gene-end transcription signals are shown as black triangles and bars, respectively, flanking each rectangle. The figure is not drawn to scale. le, leader; tr, trailer.
![Fig. 2.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8cf/470755/58a0c92db707/zpq0260452540002.gif)
Transcription of the SARS-CoV inserts into monocistronic mRNAs. LLC-MK2 cells were mock-infected (lane 7) or infected with the indicated BHPIV3 vector (lanes 1-6) at an input multiplicity of infection of 3 TCID50 per cell. Total intracellular RNA was isolated 72 h after infection, electrophoresed on a 1% agarose gel in the presence of 0.44 M formaldehyde, transferred to nylon membrane, and hybridized with α-32P-labeled double-stranded DNA probes specific for SARS S, M, E, and N, or BPIV3 N, as indicated on the left. The images were prepared with a PhosphorImager.
![Fig. 3.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8cf/470755/930856b766d0/zpq0260452540003.gif)
Expression of SARS-CoV proteins by BHPIV3 vectors. LLC-MK2 cells were infected with the individual BHPIV3 vectors (lanes 1-7) at an input multiplicity of infection of 5 TCID50 per cell. In addition, Vero cells were mock-infected (lane 9) or infected with 5 TCID50 per cell of SARS-CoV (lane 8). Cell lysates were prepared 42 h after infection, in the case of SARS-CoV, or 72 h after infection, in the case of the BHPIV3 vectors, denatured under reducing conditions, subjected to SDS/PAGE in 4-12% gradient gels, and transferred to nitrocellulose. SARS-CoV proteins were detected by using convalescent serum from an African green monkey that had been infected with SARS-CoV. The BHPIV3 F protein was detected in a parallel blot by using HPIV3-specific rabbit hyperimmune serum (Lower). Detection of bound antibodies was done with horseradish peroxidase-conjugated goat anti-human (in the case of the anti-SARS-CoV serum) or anti-rabbit (in the case of the anti-HPIV3 serum) antibody, respectively, and visualized by chemiluminescence.
![Fig. 4.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8cf/470755/70a655ccd510/zpq0260452540004.gif)
Indirect immunofluorescence of LLC-MK2 cells infected with BHPIV3 vectors. Cells on cover slips were infected at an input multiplicity of infection of 0.05 TCID50 with the BHPIV3 vectors listed to the left, incubated for 24 h, fixed with 4% paraformaldehyde, and permeabilized with 1% Triton X-100. SARS-CoV proteins were visualized (Left) by incubation with convalescent serum from a SARS-CoV-infected African green monkey followed by an Alexa488-conjugated goat anti-human antibody (Molecular Probes). BHPIV3 proteins were visualized (Center) by incubation with convalescence serum from HPIV3-infected hamsters, followed by Alexa594-conjugated goat anti-hamster antibody (Molecular Probes). Nuclear chromatin staining (blue) was performed with 4′,6-diamidino-2-phenylindole (Sigma).
Similar articles
-
Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL. Bukreyev A, et al. Lancet. 2004 Jun 26;363(9427):2122-7. doi: 10.1016/S0140-6736(04)16501-X. Lancet. 2004. PMID: 15220033 Free PMC article.
-
See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CPY, Hogan RJ, Rowe T, Zitzow LA, Karunakaran KP, Hitt MM, Graham FL, Prevec L, Mahony JB, Sharon C, Auperin TC, Rini JM, Tingle AJ, Scheifele DW, Skowronski DM, Patrick DM, Voss TG, Babiuk LA, Gauldie J, Roper RL, Brunham RC, Finlay BB. See RH, et al. J Gen Virol. 2006 Mar;87(Pt 3):641-650. doi: 10.1099/vir.0.81579-0. J Gen Virol. 2006. PMID: 16476986
-
Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G. Liu YV, et al. Vaccine. 2011 Sep 2;29(38):6606-13. doi: 10.1016/j.vaccine.2011.06.111. Epub 2011 Jul 14. Vaccine. 2011. PMID: 21762752 Free PMC article.
-
Vaccine design for severe acute respiratory syndrome coronavirus.
He Y, Jiang S. He Y, et al. Viral Immunol. 2005;18(2):327-32. doi: 10.1089/vim.2005.18.327. Viral Immunol. 2005. PMID: 16035944 Review.
-
Cavanagh D. Cavanagh D. Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198. Avian Pathol. 2003. PMID: 14676007 Free PMC article. Review.
Cited by
-
Evaluation of candidate vaccine approaches for MERS-CoV.
Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Wang L, et al. Nat Commun. 2015 Jul 28;6:7712. doi: 10.1038/ncomms8712. Nat Commun. 2015. PMID: 26218507 Free PMC article.
-
Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, Tsang AK, Xiao X, To KK, Lau SK, Woo PC, Zheng BJ, Wang M, Yuen KY. Chan KH, et al. J Infect. 2013 Aug;67(2):130-40. doi: 10.1016/j.jinf.2013.03.015. Epub 2013 Apr 10. J Infect. 2013. PMID: 23583636 Free PMC article.
-
Begum J, Mir NA, Dev K, Buyamayum B, Wani MY, Raza M. Begum J, et al. Transbound Emerg Dis. 2021 May;68(3):1111-1124. doi: 10.1111/tbed.13804. Epub 2020 Sep 23. Transbound Emerg Dis. 2021. PMID: 32815655 Free PMC article. Review.
-
Shi SQ, Peng JP, Li YC, Qin C, Liang GD, Xu L, Yang Y, Wang JL, Sun QH. Shi SQ, et al. Mol Immunol. 2006 Apr;43(11):1791-8. doi: 10.1016/j.molimm.2005.11.005. Epub 2006 Jan 19. Mol Immunol. 2006. PMID: 16423399 Free PMC article.
-
Du L, Zhao G, Chan CC, Li L, He Y, Zhou Y, Zheng BJ, Jiang S. Du L, et al. Viral Immunol. 2010 Apr;23(2):211-9. doi: 10.1089/vim.2009.0090. Viral Immunol. 2010. PMID: 20374001 Free PMC article.
References
-
- World Health Organization (2003) Wkly. Epidemiol. Rec. 78, 81-83. - PubMed
-
- Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Penaranda, S., Bankamp, B., Maher, K., Chen, M. H., et al. (2003) Science 300, 1394-1399. - PubMed
-
- Marra, M. A., Jones, S. J., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S., Khattra, J., Asano, J. K., Barber, S. A., Chan, S. Y., et al. (2003) Science 300, 1399-1404. - PubMed
-
- Lai, M. M. & Holmes, K. V. (2001) in Fields Virology, eds. Knipe, D. M. & Howley, P. M. (Lippincott, Philadelphia), Vol. 2, pp. 1163-1203.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous